Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.
about
Emerging targets and novel approaches to Ebola virus prophylaxis and treatmentFiloviruses: One of These Things is (not) Like the OtherAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksPre-symptomatic diagnosis and treatment of filovirus diseasesNovel approaches and challenges to treatment of central nervous system viral infectionsDelayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus MacaquesNeglected filovirusesEbola virus - from neglected threat to global emergency state.Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target.Ebola: Implications and Perspectives.Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies.Treatment of ebola virus disease.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infectionMechanisms of immunity in post-exposure vaccination against Ebola virus infection.Improving attrition rates in Ebola virus drug discovery.DNA and RNA derivatives to optimize distribution and deliveryEbola: Working Toward Treatments and Vaccines.Ebola Virus Infection: Overview and Update on Prevention and Treatment.Ebola virus disease.Potential and emerging treatment options for Ebola virus disease.Ebola virus outbreak, updates on current therapeutic strategies.Development of Small-Molecule Antivirals for Ebola.Nucleic acid-based drugs against emerging zoonotic viruses.Oligonucleotide therapeutics: chemistry, delivery and clinical progress.Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process.Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.Therapeutics for postexposure treatment of Ebola virus infection.Discovering Drugs for the Treatment of Ebola Virus.Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5.Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides.Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.Ebola: history, treatment, and lessons from a new emerging pathogen.Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus
P2860
Q24597625-6A4C55E8-6C7A-4243-962A-527B2C3AA4D5Q26783063-62CA899A-8B3E-4A7A-AB57-A4B57EDDED0DQ26801423-3A5F9975-B097-4E22-A0B6-A5B17BA20256Q26823831-CFE6EC91-DDCA-4BAA-B98C-D8EAB0A9930DQ26862449-BFFFC659-FCBE-4FE4-8308-202A5F42791AQ27303778-092452AA-D45E-424E-9DF9-6C1410E6FF4CQ28383265-584C61A6-F259-4073-B4B8-96076311B97AQ30245153-4B0FF355-1B18-4E6F-A904-B6D1C483DBEFQ30251949-4E7046F8-02D7-4325-95B0-C38BBC22B695Q30252022-2EE2B90A-1C8F-4498-96FF-99C51DC22F2EQ30376138-D101C3BD-891F-4569-97BD-F1398DE28FF3Q30378672-DB77171A-1D80-4485-973B-F4B2762CEBC5Q34435035-7472A940-4D28-4D84-9DF1-794A50DB660AQ34460182-EAE5E7D4-3BE7-43A0-BDF0-1ECC5A2DF9FFQ34463780-F2C95356-3489-4F8F-BE7A-B8780E301C5CQ35111132-AAA3FD6B-436B-4D0B-866B-91B1F4C8A57AQ35192417-FF657963-601A-4556-A505-5CC4BD4C4C95Q35678774-1361C14D-9F82-4EFE-9F64-4BB3DA657586Q35858691-CB9C317B-275E-4095-8604-CBD8B7AF41FBQ35896458-AD160B5F-3C1D-42BF-A3CD-89A2F745FE17Q36363253-AAD92856-A9EB-49A6-B553-61C20DDB3349Q36449434-B7964978-F284-47FE-A090-B3F341CDACDCQ38270149-0E7DBCD4-726A-4976-A8A2-3BC3E90A0580Q38473251-D04F7923-55ED-49A0-A7ED-45DAD0FD8C90Q38546746-D2C45613-57EC-4731-B151-EF39513F9AE4Q38591847-16121961-5AE9-4F68-97CA-8C5E1111A7DFQ38618638-6FD7B83A-3678-46D2-B36A-20D2351114CFQ38880125-8FC9B481-5438-42C0-BA81-D2CBC4508794Q38962711-0AAFB818-0003-4B55-8967-6C06E6607527Q38980947-735FD9F0-60E0-4CD9-B6A2-BD88F6052B63Q40039706-9DA0D8D3-4AFF-43ED-AAB0-88D1C6651AD2Q40054337-EFE6F2BB-CAA8-4A23-B2F6-94B24ECC51F6Q40054412-B223F1BD-14C8-4413-86A8-301BEC88BCB2Q41387647-8736F76E-4D90-4449-A60B-85F1E6CEEB1DQ42753196-8AECB107-685A-4EB2-BB02-97C021B1B6C4Q43148108-38B336D7-4DD9-44A4-AF17-2A83A4CE9A8CQ53687216-D2DFDB14-42EC-4BCF-B62F-4FBBB1C2DA7CQ56535662-45DDF890-0E20-48EC-9799-8F674D0E89BA
P2860
Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Discovery and early developmen ...... and Marburg virus infections.
@ast
Discovery and early developmen ...... and Marburg virus infections.
@en
type
label
Discovery and early developmen ...... and Marburg virus infections.
@ast
Discovery and early developmen ...... and Marburg virus infections.
@en
prefLabel
Discovery and early developmen ...... and Marburg virus infections.
@ast
Discovery and early developmen ...... and Marburg virus infections.
@en
P2093
P2860
P356
P1433
P1476
Discovery and early developmen ...... and Marburg virus infections.
@en
P2093
Dan V Mourich
Jay B Wells
Lisa S Welch
Nicole L Garza
Patrick L Iversen
Rekha G Panchal
Travis K Warren
P2860
P304
P356
10.3390/V4112806
P50
P577
2012-11-06T00:00:00Z